| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Akebia Therapeutics, Inc. (AKBA) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. AKBA is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.46M | $4.02M | - | |
| CFO | 320.0K | $371.2K | - | |
| Dir | 160.9K | $186.7K | - | |
| Dir | 129.5K | $150.2K | - | |
| VP | 119.0K | $138.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2016 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,401 | $8.95 | $12,545.67 | -1.9% | |
| Jul 6, 2016 | Nash Duane | Director | Sell | 1,980 | $7.48 | $14,818.52 | -6.3% | |
| Jul 5, 2016 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,402 | $7.47 | $10,468.03 | -1.9% | |
| Jul 5, 2016 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,557 | $7.47 | $11,625.34 | -1.8% | |
| Apr 4, 2016 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,556 | $9.41 | $14,641.96 | -1.8% | |
| Apr 4, 2016 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,401 | $9.41 | $13,183.41 | -1.8% | |
| Jan 4, 2016 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,811 | $12.28 | $22,239.08 | -2.7% | |
| Oct 2, 2015 | Nash Duane | Director | Sell | 996 | $8.65 | $8,617.29 | -3.1% | |
| Oct 2, 2015 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,484 | $8.67 | $12,859.90 | -2.2% | |
| Jul 2, 2015 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,484 | $9.54 | $14,160.48 | -2.2% |